A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis Genovese, M. C., van Vollenhoven, R., Bloom, B. J., Jiang, J. G., Kinnman, N. WILEY-BLACKWELL. 2013: 3320

View details for Web of Science ID 000327692600044